Mereo Biopharma Group Plc ADR (NASDAQ: MREO) Stock: Does It Have Room To Grow?

In the last trading session, 1.78 million Mereo Biopharma Group Plc ADR (NASDAQ:MREO) shares changed hands as the company’s beta touched 0.88. With the company’s per share price at $3.06 changed hands at -$0.28 or -8.38% during last session, the market valuation stood at $473.47M. MREO’s last price was a discount, traded about -64.05% off its 52-week high of $5.02. The share price had its 52-week low at $2.53, which suggests the last value was 17.32% up since then. When we look at Mereo Biopharma Group Plc ADR’s average trading volume, we note the 10-day average is 1.19 million shares, with the 3-month average coming to 878.20K.

Analysts gave the Mereo Biopharma Group Plc ADR (MREO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.12. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended MREO as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. Mereo Biopharma Group Plc ADR’s EPS for the current quarter is expected to be 0.01.

Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information

Instantly MREO was in red as seen at the end of in last trading. With action -18.62%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -12.57%, with the 5-day performance at -18.62% in the red. However, in the 30-day time frame, Mereo Biopharma Group Plc ADR (NASDAQ:MREO) is -20.52% down. Looking at the short shares, we see there were 8.03 million shares sold at short interest cover period of 8.42 days.

The consensus price target for the stock as assigned by Wall Street analysts is 7.5, meaning bulls need an upside of 59.2% from its current market value. According to analyst projections, MREO’s forecast low is 4 with 8 as the target high. To hit the forecast high, the stock’s price needs a -161.44% plunge from its current level, while the stock would need to soar -30.72% for it to hit the projected low.

Mereo Biopharma Group Plc ADR (MREO) estimates and forecasts

Data shows that the Mereo Biopharma Group Plc ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -26.27% over the past 6 months, a 90.00% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach 2.58% up from the last financial year.

Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 9.48M. 5 analysts are of the opinion that Mereo Biopharma Group Plc ADR’s revenue for the current quarter will be 6.59M.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 41.78%. The 2025 estimates are for Mereo Biopharma Group Plc ADR earnings to decrease by -10.71%.

MREO Dividends

Mereo Biopharma Group Plc ADR is expected to release its next quarterly earnings report in February.

Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 1.02% of Mereo Biopharma Group Plc ADR shares while 70.58% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 71.30%. There are 70.58% institutions holding the Mereo Biopharma Group Plc ADR stock share, with RUBRIC CAPITAL MANAGEMENT LP the top institutional holder. As of 2024-06-30, the company held 2.1859% of the shares, roughly 15.31 million MREO shares worth $55.11 million.

ADAGE CAPITAL PARTNERS GP, L.L.C. holds the second largest percentage of outstanding shares, with 1.6838% or 11.79 million shares worth $42.45 million as of 2024-06-30.

Among Mutual Funds, the top two as of Aug 31, 2024 were Tema ETF Tr-Tema Oncology ETF and Tema ETF Tr-Tema GLP-1, Obesity & Cardiometabolic ETF . With 311.76 shares estimated at $0.95 million under it, the former controlled 0.01% of total outstanding shares. On the other hand, Tema ETF Tr-Tema GLP-1, Obesity & Cardiometabolic ETF held about 0.01% of the shares, roughly 526.14 shares worth around $1.61 million.